special populations
Recently Published Documents


TOTAL DOCUMENTS

1280
(FIVE YEARS 241)

H-INDEX

35
(FIVE YEARS 6)

2022 ◽  
pp. 76-82
Author(s):  
Steve Berta ◽  
Howard Blonsky ◽  
James Wogan
Keyword(s):  

2021 ◽  
Vol 12 (1) ◽  
pp. 6
Author(s):  
Cristina Ramo-Tello ◽  
Yolanda Blanco ◽  
Luis Brieva ◽  
Bonaventura Casanova ◽  
Eva Martínez Cáceres ◽  
...  

Minimizing the risk of relapse is essential in multiple sclerosis (MS). As none of the treatments currently available are capable of completely preventing relapses, treatment of these episodes remains a cornerstone of MS care. The objective of this manuscript is to reduce uncertainty and improve quality of care of this neurological process. This article addresses definitions of key concepts, recommendations for clinical examination, classification criteria, magnetic resonance imaging, biomarkers, and specific therapeutic counsels including special populations such as pregnant and breastfeeding women, and children. An algorithm for treating MS relapses is also provided.


2021 ◽  
pp. 205-237
Author(s):  
Christine M. Madla ◽  
Francesca K. H. Gavins ◽  
Sarah J. Trenfield ◽  
Abdul W. Basit
Keyword(s):  

2021 ◽  
Vol 12 ◽  
Author(s):  
Daniel O’Connor ◽  
Viviana Moschese ◽  
Federico Martinon-Torres ◽  
Paolo Palma
Keyword(s):  

2021 ◽  
pp. 165-194
Author(s):  
Sunny Harris Rome
Keyword(s):  

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. 271-271
Author(s):  
Patricia Jones

Abstract Dr. Jones will discuss the work of the NIA Office of Special Populations. Dr. Jones will also be available for small group discussion.


2021 ◽  
Vol 42 (06) ◽  
pp. 859-872
Author(s):  
Emanuele Palomba ◽  
Valeria Castelli ◽  
Giulia Renisi ◽  
Alessandra Bandera ◽  
Andrea Lombardi ◽  
...  

AbstractInfluenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants.


2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Edward Perera ◽  
Xi Ming Zhu ◽  
Nolan S. Horner ◽  
Asheesh Bedi ◽  
Olufemi R. Ayeni ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document